摘要
目的探究重组人白细胞介素-11治疗急性白血病化疗后血小板减少的临床效果。方法选择2012年3月~2014年3月本院收治的48例急性白血病患者,随机分为观察组与对照组,各24例,再选24例为正常对照组。对照组采用常规化疗,观察组在此基础上采用重组人白细胞介素-11治疗。治疗后比较观察组与对照组血小板指标与不良反应发生率,比较3组血浆促血小板生成素（Tpo）水平、网织血小板绝对值（RPC）。结果两组血小板最低值比较差异无统计学意义（P〉0.05）;观察组血小板最高值高于对照组,血小板恢复时间短于对照组,血小板输注量少于对照组,差异均有统计学意义（P〈0.05）。观察组不良反应发生率明显低于对照组,差异有统计学意义（P〈0.05）。两组患者化疗前后血RPC及Tpo水平与正常对照组比较差异均有统计学意义（P〈0.05）;观察组化疗1、2周后血RPC及Tpo水平与化疗前及对照组比较差异均有统计学意义（P〈0.05）;对照组化疗1周后血RPC及Tpo水平与化疗前比较差异均有统计学意义（P〈0.05）。结论重组人白细胞介素-11治疗急性白血病化疗后血小板减少的效果确切,可有效促进生成血小板,降低血小板低下危险性,值得临床推广应用。
Objective To study clinical efficacy of human recombinant interleukin-11 in the treatment of thrombocytopenia and acute leukemia after chemotherapy. Methods 48 patients with acute leukemia in our hospital from March2012 to March 2014 were selected and randomly divided into observation group and control group,24 cases in each group.Another 24 cases of normal people were chosen in normal control group.Conventional chemotherapy was used in control group,human recombinant interleukin-11 was applied in observation group on the basis of control group,After the treatment,the incidence rate of adverse reaction and the platelet indexes were compared between observation group and control group.Plasma Tpo level and RPC were compared among three groups. Results The lowest value of platelet in two groups was compared,with no statistical difference（P 〉0.05）.Highest value of platelet in observation group was higher than that in control group,platelet recovery time in observation group was shorter than that in control group,platelet transfusion volume in observation group was less than that in control group,with statistical difference（P〈0.05）.Incidence rate of adverse reaction in observation group was significantly lower than that in control group,with statistical difference（P〈0.05）.Compared with normal control group,RPC and Tpo level in two groups before and after chemotherapy had statistical difference（P〈0.05）.Compared with before chemotherapy and control group,RPC and Tpo level in observation group after chemotherapy of 1,2-week had statistical difference（P〈0.05）.Compared with before chemotherapy,RPC and Tpo level in control group after chemotherapy of 1 week had statistical difference（P〈0.05）. Conclusion The efficacy of human recombinant interleukin-11 in the treatment of thrombocytopenia and acute leukemia after chemotherapy is good,can effectively promote platelet production and reduce the risk of thrombocytopenia,is worthy of clinical promotion and application.
出处
《中国当代医药》
2014年第33期84-86,共3页
China Modern Medicine
